# Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

> **NCT00263328** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 46 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550

## Key facts

- **NCT ID:** NCT00263328
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-06
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263328, "Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00263328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*